Moving on to the subject of this post, I do believe Ivermectin is one of the most relevant repurposed drugs in terms of its potential to add value in oncology. However, this is not the only reason that motivates me now to write about it. Instead, it is because of multiple questions of people regarding the most common and relevant Ivermectin doses used in oncology. As a result, the post below will give a specific attention to that aspect. Next to that, the other very important reason to me is that positive case reports started to emerge, after its use by oncology cancer patients.
The gentleman, Rick, had widespread metastatic disease affecting the liver and lymph nodes and was told his cancer was “unsurvivable.” At most, he had six months left, according to his Oncologist.
Following adding Ivermectin, his tumor markers dropped from 1489 to 4.7, and his metastases calcified and shrunk. This was felt due to the anti-metastatic effect of Ivermectin as it suppresses the WnT Pathway, which cancer stem cells rely upon.
In 2004, the US Congress passed an amendment to the Federal Food, Drug and Cosmetic Act known as Emergency Use Authorization (EUA). This piece of legislature legalized an anti-regulatory pathway to allow experimental medical interventions to be expedited without proper safety evaluation in the event of bioterrorist threats and national health emergencies such as pandemics. At the time, passage of the EUA amendment made sense because it was partially in response to the 2001 anthrax attacks and the US’s entry into an age of international terrorism. However, the amendment raises some serious considerations.